MedTrace Logo

Safety and Efficacy of Two Dosages of Diractin® in Osteoarthritis (OA)

NCT00716547 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1399

Last updated 2009-10-16

No results posted yet for this study

Summary

The purpose of this study is to provide replicated evidence of safety and efficacy of 50 mg and 100 mg ketoprofen in Diractin®.

Conditions

  • Osteoarthritis of the Knee

Interventions

DRUG

ketoprofen in Diractin®

50 mg (b.i.d.)

DRUG

ketoprofen in Diractin®

100 mg (b.i.d.)

DRUG

Placebo

b.i.d.

DRUG

celecoxib

100 mg (b.i.d.)

Sponsors & Collaborators

  • IDEA AG

    lead INDUSTRY

Principal Investigators

  • IDEA AG Clinical Trial · IDEA AG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
46 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-03-31
Completion
2009-05-31

Countries

  • Czechia
  • Germany
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00716547 on ClinicalTrials.gov